Clinical Cancer Research CR Balducci Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mortara, L.
Right arrow Articles by Accolla, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mortara, L.
Right arrow Articles by Accolla, R. S.
Clinical Cancer Research Vol. 12, 3435-3443, June 1, 2006
© 2006 American Association for Cancer Research


Cancer Therapy: Preclinical

CIITA-Induced MHC Class II Expression in Mammary Adenocarcinoma Leads to a Th1 Polarization of the Tumor Microenvironment, Tumor Rejection, and Specific Antitumor Memory

Lorenzo Mortara1, Patrizia Castellani2, Raffaella Meazza4, Giovanna Tosi1, Andrea De Lerma Barbaro1, Francesco A. Procopio1, Alberto Comes3, Luciano Zardi4,5, Silvano Ferrini3 and Roberto S. Accolla1

Authors' Affiliations: 1 Department of Clinical and Biological Sciences, School of Medicine, University of Insubria, Varese, Italy; 2 Laboratory of Cellular Biology and 3 Laboratory of Immunological Therapy, Istituto Nazionale per la Ricerca sul Cancro; 4 Laboratory of Experimental and Clinical Immunology, Istituto G. Gaslini; and 5 Unit of Innovative Therapy, Advanced Biotechnology Center, Genova, Italy

Requests for reprints: Roberto S. Accolla, Department of Clinical and Biological Sciences, School of Medicine, University of Insubria, Via Ottorino Rossi, 9, 21100 Varese, Italy: Phone: 39-348-3034698; Fax: 39-0332-217219; E-mail: roberto.accolla{at}uninsubria.it.

Purpose: We have shown previously that the MHC class II–negative murine TS/A adenocarcinoma is rejected in vivo if induced to express MHC class II molecules by transfection of the MHC class II transactivator CIITA. In this study, we explored the immunologic basis of tumor rejection and the correlation between histopathology of tumor tissue and immune rejection.

Experimental Design: Stable TS/A-CIITA transfectants were generated and injected into mice. In vivo cell depletion, immunohistochemistry of tumor tissues, and immune functional assays were done to assess the cellular and immunologic basis of rejection.

Results: Ninety-two percent of mice injected with TS/A-CIITA rejected the tumor and were completely resistant to challenge with parental TS/A. Only CD4+ and CD8+ cells were required for rejection. The tumor microenvironment in TS/A-CIITA-injected mice changed dramatically when compared with the TS/A parental-injected mice. Rapid infiltration with CD4+ T cells followed by dendritic cells, CD8+ T cells, and granulocytes was observed. Importantly, TS/A-CIITA cells could act as antigen-presenting cells because they process and present nominal antigens to CD4+ T cells. Tumor-specific CD4+ T cells of TS/A-CIITA-injected mice had the functional characteristics of Th1 cells and produced IFN-{gamma} and this was relevant for generation and maintenance of protective antitumor response, because IFN-{gamma} knockout mice were no longer rejecting TS/A-CIITA tumor cells.

Conclusion: CIITA-dependent MHC class II expression confers to TS/A tumor cells the capacity to act as a protective vaccine against the tumor by triggering tumor antigen presentation to T helper cells, antitumor polarization of cellular and soluble components of the tumor microenvironment, and establishment of antitumor immune memory.




This article has been cited by other articles:


Home page
Int ImmunolHome page
L. Mortara, V. Frangione, P. Castellani, A. De Lerma Barbaro, and R. S. Accolla
Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions
Int. Immunol., June 1, 2009; 21(6): 655 - 665.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
A. De Lerma Barbaro, A. De Ambrosis, B. Banelli, G. L. Pira, O. Aresu, M. Romani, S. Ferrini, and R. S. Accolla
Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN-{gamma} in promyelocytic cells
Int. Immunol., November 1, 2008; 20(11): 1457 - 1466.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. C. de Bruin, C. J.H. van de Velde, J. H. J.M. van Krieken, C. A.M. Marijnen, and J. P. Medema
Epithelial Human Leukocyte Antigen-DR Expression Predicts Reduced Recurrence Rates and Prolonged Survival in Rectal Cancer Patients
Clin. Cancer Res., February 15, 2008; 14(4): 1073 - 1079.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.